急性肾损伤的新型生物标志物研究进展

Research Progress of Novel Biomarkers for Acute Kidney Injury

急性肾损伤(AKI)的早期诊治是改善预后,降低病死率的关键。而基于血清肌酐、尿量的AKI诊断在临床应用中存在不足,其敏感性和特异性均不高,会导致最佳干预时机的错失,所以进一步探求AKI的新型生物标志物意义重大。在AKI的早期识别和预后评估方面,新型标志物均优于传统生物标志物。虽然新型生物标志物可弥补传统标志物的不足,更好地进行AKI的早期识别和预后改善,但未来仍需要更全面的研究以确定其临床效用。

Early diagnosis and treatment of acute kidney injury（AKI） is the key to improve prognosis and reduce mortality.However,the diagnosis of AKI based on serum creatinine and urine volume is insufficient in clinical application,and its sensitivity and specificity are not high,which will lead to missing of optimal intervention opportunity.Therefore,it is of great significance to further explore new biomarkers of AKI.In the early recognition and prognosis evaluation of AKI, the new biomarkers are superior to the traditional biomarkers.Although the new biomarkers can make up for the deficiency of the traditional markers and better identify AKI early and improve its prognosis,more comprehensive research is still needed in the future to determine its clinical utility.